Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 to Treat Cognitive Impairment in Schizophrenia
Reuters
Oct 03, 2025
<a href="https://laohu8.com/S/ANRO">Alto Neuroscience</a> Receives FDA <a href="https://laohu8.com/S/FTRK">Fast Track</a> Designation for ALTO-101 to Treat Cognitive Impairment in Schizophrenia
Alto Neuroscience Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational drug ALTO-101 for the treatment of cognitive impairment associated with schizophrenia $(CIAS)$. This regulatory milestone highlights the urgent need for new therapies targeting CIAS, a condition that significantly affects daily functioning in patients with schizophrenia and currently has no approved treatments. ALTO-101, a novel small molecule PDE4 inhibitor, has shown promising results in Phase 1 trials by improving cognitive performance and related brain activity measures. The Fast Track designation will facilitate closer collaboration with the FDA and may expedite the drug's development and review process. This designation was granted solely to Alto Neuroscience Inc.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251003096029) on October 03, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.